Seattle Children's Hospital & Medical Center

An investigation into the study drug’s role is just getting started, but a Phase I clinical trial of 2seventy Bio, Inc. ’s SC-DARIC33 chimeric antigen receptor T-cell (CAR-T) therapy candidate in acu

Lysogene Licenses Gene Therapy Candidate From Yeda Research Advancing a collaboration inked in July 2020, gene therapy specialist Lysogene SA said on 12 April that it is taking its option to license

Be Biopharma has raised a $130m series B financing from new and existing investors to bring what it describes as a novel type of cell therapy – Engineered B Cell Medicines (BeCM) – closer to the clin

Scrip regularly reviews technology transfer activity across the biopharmaceutical sector. Recent editions of Tech Transfer Roundup focused on oncology and COVID-19 deals. This reviews the rest of